The Medicines and Healthcare products Regulatory Agency (MHRA) has announced strengthened safety warnings for all products containing botulinum toxin type A, following rare reports of botulism linked to their use. The update, issued on July 15, 2026, aims to raise awareness about iatrogenic botulism—a life-threatening condition caused by the spread of the toxin beyond the intended injection site.
Background on Botulinum Toxin Products
Botulinum toxin type A is a prescription-only medicine in the UK, authorised for both medical and cosmetic procedures. It is used to treat conditions such as muscle spasms, hyperhidrosis (excessive underarm sweating), and overactive bladder. However, in rare cases, the toxin can spread from the injection area, leading to botulism, a serious illness that attacks the nervous system.
Strengthened Safety Warnings
To mitigate risks, the MHRA has collaborated with manufacturers to improve product labels and patient information leaflets. These updates highlight the symptoms of botulism, which include muscle weakness, breathing difficulties, slurred speech, and difficulty swallowing. Patients experiencing these symptoms within four weeks of treatment are urged to seek immediate medical attention.
Dr Alison Cave, MHRA Chief Safety Officer, stated: "Botulinum toxin products are effective for a number of different medical and cosmetic purposes when used correctly. However, these strengthened warnings are an important reminder that, in rare cases, serious side effects can occur. It is vital that healthcare professionals and patients are aware of the symptoms of botulism and act quickly if they arise as this is a medical emergency."
Public Health Advice
Dr Martin Bewley, Consultant in Health Protection from the UK Health Security Agency (UKHSA), added: "While botulism is a rare infection, it can be serious. There are effective treatments available and we recommend seeking immediate medical advice if you have had a recent treatment and are having symptoms such as difficulty swallowing." He advised contacting NHS 111 (or the local equivalent in Northern Ireland) for further advice and seeking immediate medical attention.
The MHRA strongly urges the public to avoid unlicensed products and seek treatment only from appropriately qualified practitioners. The agency’s Criminal Enforcement Unit is actively investigating a rise in hospital admissions linked to unlicensed and counterfeit botulinum toxin products, which fail to meet UK safety and quality standards.
Risk Factors and Safety Tips
The risk of adverse reactions may be higher in certain circumstances, including patients with underlying neurological disorders, a history of dysphagia (difficulty swallowing), or a history of aspiration (breathing in foreign material). High doses, use outside licensed indications, or injection into unapproved sites also increase risk.
To stay safe, patients should ensure their practitioner is properly qualified, confirm that any product used is officially authorised in the UK, and report any suspected side effects through the MHRA’s Yellow Card scheme. The MHRA continues to monitor the safety of these medicines, including side effects and emerging evidence.
